222834-30-2

Basic information

• Product Name: (-)-2(S)-Ethoxy-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]propionic acid
• Synonyms: Ragaglitazar; NNC-61-0029; (-)-DRF-2725; NN-622; (2R)-2-ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid; 2-ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid
• CAS NO: 222834-30-2
• Molecular Formula: C₂₅H₂₅NO₅
• Molecular Weight: 419.4697
• Mol File: 222834-30-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 608.6°C at 760 mmHg
• Flash Point: 321.9°C
• Density: 1.241g/cm³
• Vapor Pressure: 1.15E-15mmHg at 25°C
• Refractive Index: 1.606
• CAS DataBase Reference: (-)-2(S)-Ethoxy-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-2(S)-Ethoxy-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]propionic acid(222834-30-2)
• EPA Substance Registry System: (-)-2(S)-Ethoxy-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]propionic acid(222834-30-2)

Safety Data

• Hazardous Substances Data: 222834-30-2(Hazardous Substances Data)

Usage

General Description

(-)-2(S)-Ethoxy-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]propionic acid is a complex chemical compound with an intricate molecular structure. (-)-2(S)-Ethoxy-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]propionic acid is a derivative of propionic acid, a carboxylic acid, and contains additional functional groups such as ethoxy and phenoxazin-10-yl. It exhibits chirality, with the S configuration at the second carbon atom. (-)-2(S)-Ethoxy-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]propionic acid may have potential applications in pharmaceuticals due to its unique structure and functional groups, and further research may be necessary to fully understand its properties and potential uses.

Upstream product

• 222834-42-6 (S)-methyl 3-(4-(2-(10H-phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropanoate 
• 222834-28-8 [(2S),N(1S)]-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxy-N-(2-hydroxy-1-phenylethyl)propanamide 
• 222834-11-9 (+/-)-methyl 3-(4-(2-(10H-phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropanoate 
• 325793-74-6 (S)-methyl 2-ethoxy-3-(4-hydroxyphenyl)propanoate 
• 493031-10-0 Ethyl-(2R/2S)-2-ethoxy 3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate 
• 222835-03-2 3-(4-benzyloxy-phenyl)-2-ethoxy-acrylic acid ethyl ester 
• 325793-71-3 (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid isopropyl ester 
• 325793-65-5 (2S)-2-Ethoxy-3-(4-hydroxyphenyl)propanoic acid 
• 197299-16-4 ethyl 2-ethoxy-3-(4-hydroxy-phenyl)-propionate 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 222835-09-8 2-(10H-Phenoxazin-10-yl)ethyl methanesulfonate 
• 92199-64-9 2-(10H-phenoxazin-10-yl)-1-ethanol 
• 59012-91-8 2,2-dimethyl-propionic acid 4-hydroxymethyl-phenyl ester 
• 623-05-2 (4-hydroxyphenyl)methanol 

Downstream Products

• 222834-28-8 [(2S),N(1S)]-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxy-N-(2-hydroxy-1-phenylethyl)propanamide 
• 222834-22-2 (+/-) 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, sodium salt 
• 264268-43-1 (+/-) 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, potassium salt 

Relevant articles and documents

Asymmetric phase-transfer catalyzed glycolate alkylation, investigation of the scope, and application to the synthesis of (-)-ragaglitazar

Asymmetric glycolate alkylation using a protected acetophenone surrogate under solid-liquid phase-transfer conditions is a new approach to the synthesis of 2-hydroxy esters and acids. Diphenylmethyloxy-2,5-dimethoxyacetophenone 1 with a trifluorobenzyl ci

Process for the preparation of new antidiabetic agents

The present invention relates to an improved process for the preparation of novel antidiabetic compounds having formula (1) where R1represents hydrogen or lower alkyl group and X represents hydrogen or halogen atom.

Crystalline R-guanidines, arginine or (L)-arginine (2S)-2-ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate

The present invention relates to crystalline R-guanidines of (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparations and its use as therapeutic agents. More specifically the present invention relates to crystalline Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, preferably (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparation and its use as therapeutic agent.